Abstract
Backgroun Early identification of the occurrence and progression of coronary ischemic events is particularly important for the diagnosis and treatment of coronary heart disease complicated with tumor. Therefore, it is of great significance to analyze biomarkers and regulatory factors of recurrent myocardial infarction after first myocardial infarction.In order to specify the regulatory factor of coronary heart disease or myocardial infarction on tumor occurrence and metastasis and clinical survival effect, we select from GEO database for the first time of recurrence after myocardial infarction, myocardial infarction, microarray data set, the comprehensive evaluation of the data set is the key cut genes and cancer, tumor prognosis, the tumor extends into the immune level of mutation, etc.The purpose of this study is to discover the role of myocardial infarction regulatory factors in cancer.
Methods GSE48060 chip data set was downloaded from GEO database to obtain gene expression profiles of blood samples from normal cardiac function control and first AMI patients within 48 hours after the first myocardial infarction.GEO2R online tool and Excel software were used to screen the differential genes between the reinfarction samples and the normal samples in the GSE48060 chip data set.DAVID database was used for enrichment analysis of GO and KEGG of DEGs.The PPI network was constructed and visualized by Using The STRING database and Cytoscape software, and the key genes were screened by the CytoHubba plug-in of Cytoscape software.TIMER database and GEPIA2 website were used to analyze and verify the expression levels of key genes between tumor tissues and normal tissues in generalized carcinoma.GEPIA2 website was used to analyze the correlation between key genes and tumor prognosis.The correlation between key gene expression and tumor purity and each immune cell was analyzed by TIMER database.CBioPortal website was used to analyze the mutation and correlation of key genes in tumors.
Results Through analysis, the difference genes of 17 GSE48060 chip data sets of reinfarction samples and normal samples were obtained, and the above genes were all down-regulated genes.Five key genes were obtained through constructing PPI network, which were GART, SOD2, KLRF1, ERAP2 and CXCL5.According to the TIMER result, The expression level of GART in BLCA, BRCA, CHOL, COAD, ESCA, HNSC, KICH, KIRC, LIHC, LUAD, LUSC, PRAD, READ, STAD and THCA was significantly different from that in normal tissues (P < 0.001).The expression levels of SOD2 in BRCA, ESCA, KICH, KIRC, KIRP, LUSC, SKCM and STAD were significantly different from normal tissues (P < 0.001).The expression levels of KLRF1 in BRCA, COAD, HNSC, LIHC, LUAD, LUSC, PRAD, READ, STAD and UCEC were significantly different from those in normal tissues (P < 0.001).The expression levels of ERAP2 in BRCA, KIRC and LUSC were significantly different from those in normal tissues (P < 0.001).The expression levels of CXCL5 in BRCA, COAD, ESCA, HNSC, KICH, KIRC, KIRP, LUAD, LUSC, PRAD, STAD, THCA and UCEC were significantly different from those in normal tissues (P < 0.001).The results of GEPIA2 showed that the expression levels of GART in CESC, CHOL, ESCA, KICH, LUSC, SARC and STAD showed significant differences between tumor tissues and normal tissues (P < 0.05).There were significant differences in the expression levels of SOD2 in BLCA, BRCA, ESCA, PAAD and PCPG between tumor tissues and normal tissues (P < 0.05), and there were significant differences in the expression levels of KLRF1 in LUAD and LUSC between tumor tissues and normal tissues (P < 0.05).There were significant differences in ERAP2 expression between tumor tissues and normal tissues in KICH and LUSC (P < 0.05), and there were significant differences in CXCL5 expression between tumor tissues and normal tissues in CHOL, COAD, ESCA, LUAD, LUSC, READ and STAD (P < 0.05).The results of tumor survival analysis indicated that the correlation between the overall tumor survival (OS) of GART and CESC, KIRC, LUAD, READ and SARC was statistically significant (P < 0.05).The correlation between SOD2 and TUMOR OS of SKCM was statistically significant (P < 0.05).The correlation of TUMOR OS between KLRF1 and HNSC was statistically significant (P < 0.05).The correlation between CXCL5 and TUMOR OS of KICH and KIRC was statistically significant (P < 0.05).There was statistically significant correlation between GART and LUAD’s tumor stage (P < 0.05), SOD2 and SKCM’s tumor stage (P < 0.05), CXCL5 and KICH and KIRC’s tumor stage (P < 0.05).The GART gene expression level is significantly correlated with various immune cells in CESC, KIRC, LUAD, READ and SARC.The expression level of SOD2 gene was significantly correlated with various immune cells in SKCM.The expression level of KLRF1 gene was significantly correlated with various immune cells in HNSC.The expression level of CXCL5 gene was significantly correlated with various immune cells in KICH and KIRC.The proportion of mutations in COAD, KICH, LIHC, READ, SKCM and THCA was the highest, the proportion of amplification in BRCA, ESCA, HNSC, KIRC, LUSC and STAD was the highest, and the proportion of severe deletion in LUAD and PRAD was the highest.
Conclusion The key down-regulated genes of recurrent myocardial infarction after initial myocardial infarction are related to tumor genesis, metastasis, clinical survival and immune invasion.Key down-regulated genes in recurrent myocardial infarction may serve as important biomarkers for the diagnosis and treatment of cancer.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The raw data could be obtained from online databases including the GEO, TIMER, GEPIA2, cBioPortal, and DAVID without any restrictions.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors All data produced in the present work are contained in the manuscript All data produced are available online at GEO, TIMER, GEPIA2, cBioPortal, and DAVID
